Strong contribution to Novartis ophthalmology offering expected from Xiidra

4 July 2019

The completion of the up to $5.3 billion acquisition of dry eye syndrome (DES) drug Xiidra (lifitegrast ophthalmic solution) by Novartis (NOVN: VX) from Japan’s Takeda (TYO: 4502) earlier this week is expected to significantly expand the Swiss pharma giant’s sales in this therapy sector.

“The deal will extend Novartis’ ophthalmology portfolio showing its commitment to be an ophthalmology player after the spin-off of its eye disease device unit, Alcon, earlier this year, commented Alessio Brunello, senior pharma analyst at analytics from GlobalData.

But the market for Xiidra could face a few challenges as generic versions of its main rival, Allergan’s (NYSE: AGN) Restasis (cyclosporine ophthalmic emulsion), are available due to patent loss protection in May 2019. However, Restasis targets just the sign of the disease and not the symptoms giving Xiidra a competitive advantage, he noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK